Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 10/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4846126 | 1.00 | LRRK2 (0.53) | LRRK2LMNAUSP2POLBALDH1A1 | |
| SCHEMBL4853971 | 0.83 | LRRK2 (0.48) | LRRK2LMNAUSP2POLBALDH1A1 | |
| SCHEMBL4853974 | 0.83 | LRRK2 (0.48) | LRRK2LMNAUSP2POLBALDH1A1 | |
| SCHEMBL6452235 | 0.79 | PTGDR2 (0.67) | LRRK2LMNAUSP2POLBALDH1A1 | |
| SCHEMBL30591972 | 0.79 | PTGDR2 (0.67) | LRRK2LMNAUSP2POLBALDH1A1 | |
| SCHEMBL552025 | 0.78 | LRRK2 (0.57) | LRRK2LMNAPOLBALDH1A1KDM4E | |
| SCHEMBL384896 | 0.78 | FOLH1 (0.68) | LRRK2LMNAPOLBALDH1A1KDM4E | |
| SCHEMBL5431545 | 0.77 | LRRK2 (0.63) | LRRK2LMNAUSP2POLBALDH1A1 | |
| SCHEMBL29473232 | 0.75 | LRRK2 (0.54) | LRRK2LMNAUSP2AAK1HTT | |
| SCHEMBL6492975 | 0.75 | LRRK2 (0.60) | LRRK2LMNAUSP2POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7446102-B2 | Antibacterial amide macrocycles IV | AICURIS GMBH & CO. KG (DE) | 2008-11-04 | — | — | US | disclosed |
| US-20080076745-A1 | ANTIBACTERIAL AMIDE MACROCYCLES IV | AICURIS GMBH & CO. KG (DE) | 2008-03-27 | — | — | US | disclosed |
| US-20050256037-A1 | Antibacterial amide macrocyles | BAYER HEALTHCARE AG (DE) | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076745-A1 | ANTIBACTERIAL AMIDE MACROCYCLES IV | NOD2, AAAS, AADAC | LRRK2 2027/4885LMNA 3175/4885USP2 4102/4885 |
| US-20050256037-A1 | Antibacterial amide macrocyles | AADAC, PAM, NOD2 | LRRK2 3614/4885LMNA 2711/4885USP2 2431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.